R W Herzog
Overview
Explore the profile of R W Herzog including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
1425
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Batsuli G, Meeks S, Herzog R, Lacroix-Desmazes S
Haemophilia
. 2016 Jul;
22 Suppl 5:31-5.
PMID: 27405673
Introduction: Haemophilia A is an X-linked bleeding disorder characterized by a deficiency of coagulation protein factor VIII (FVIII). A challenging complication of therapeutic FVIII infusions is the formation of neutralizing...
2.
Moghimi B, Sack B, Nayak S, Markusic D, Mah C, Herzog R
J Thromb Haemost
. 2011 May;
9(8):1524-33.
PMID: 21585650
Background: Formation of inhibitory antibodies is a frequent and serious complication of factor (F) VIII replacement therapy for the X-linked bleeding disorder hemophilia A. Similarly, hemophilia A mice develop high-titer...
3.
Nayak S, Herzog R
Gene Ther
. 2009 Nov;
17(3):295-304.
PMID: 19907498
Viral vectors are potent gene delivery platforms used for the treatment of genetic and acquired diseases. However, just as viruses have evolved to infect cells efficiently, the immune system has...
4.
Cao O, Loduca P, Herzog R
J Thromb Haemost
. 2009 Jul;
7 Suppl 1:88-91.
PMID: 19630776
The immune response to coagulation factors VIII or IX, in particular formation of inhibitory antibodies, complicates treatment of hemophilia. Therefore, a number of recent studies in animal models have explored...
5.
Nayak S, Cao O, Hoffman B, Cooper M, Zhou S, Atkinson M, et al.
J Thromb Haemost
. 2009 Jul;
7(9):1523-32.
PMID: 19583824
Background: Gene and protein replacement therapies for inherited protein deficiencies such as hemophilia or lysosomal storage disorders are limited by deleterious immune responses directed against their respective therapeutic proteins. Therefore,...
6.
Tai S, Herzog R, Margaritis P, Arruda V, Chu K, Golden J, et al.
J Thromb Haemost
. 2007 Nov;
6(2):339-45.
PMID: 18036190
Background: Activated factor X (FXa) is a vitamin K-dependent serine protease that plays a pivotal role in blood coagulation by converting prothrombin to thrombin. There are no reports of humans...
7.
Wang L, Cao O, Swalm B, Dobrzynski E, Mingozzi F, Herzog R
Gene Ther
. 2005 May;
12(19):1453-64.
PMID: 15889137
The risk of an immune response to the coagulation factor IX (F.IX) transgene product is a concern in gene therapy for the X-linked bleeding disorder hemophilia B. In order to...
8.
Liu Y, Wagner K, Robinson N, Sabatino D, Margaritis P, Xiao W, et al.
Biotechniques
. 2003 Jan;
34(1):184-9.
PMID: 12545558
Adeno-associated viral (AAV) vectors are used for in vivo gene transfer in a number of preclinical models of genetic diseases (including large-animal models) and are currently being tested in clinical...
9.
Herzog R, Hagstrom J
Am J Pharmacogenomics
. 2002 Aug;
1(2):137-44.
PMID: 12174674
The year 2000 saw the first successful treatment of a genetic disorder by gene therapy. Pediatric patients with X-linked severe combined immunodeficiency disorder (SCID-X1) received autologous CD34+ hematopoietic cells following...
10.
Arruda V, Fields P, Milner R, Wainwright L, De Miguel M, Donovan P, et al.
Mol Ther
. 2001 Dec;
4(6):586-92.
PMID: 11735343
A potential consequence of systemic administration of viral vectors is the inadvertent introduction of foreign DNA into recipient germ cells. To evaluate the safety of in vivo recombinant adeno-associated virus...